Navigation Links
Aeras awarded €11.7 million ($16 million) grant from Dutch government
Date:11/12/2010

Rockville/Berlin, 12 November 2010 The Aeras Global TB Vaccine Foundation is pleased to announce that the Netherlands Ministry of Foreign Affairs has renewed its funding to Aeras with a pledge of an additional 11.7 million over four years (2011-2014) to further its efforts to develop new vaccines to help combat the global epidemic of tuberculosis.

This expression of support represents a continuation in the long-standing collaboration between the Dutch government, Aeras and its research partners. This is the second grant to Aeras from the Netherlands Ministry of Foreign Affairs, representing a total commitment of 30.4 million to Aeras since 2006.

"The forward movement of TB vaccine candidates in the development pipeline owes a great deal to the generous support of the Dutch Ministry of Foreign Affairs and the people of the Netherlands," said Jim Connolly, President and Chief Executive Officer of the Aeras Global TB Vaccine Foundation. "We are extraordinarily grateful for their foresight and steadfast support of these potentially life saving efforts."

TB is one of the world's deadliest infectious diseases, killing nearly 2 million men, women and children every year. Despite global efforts to prevent and treat TB, the epidemic is becoming more complex and difficult to diagnose and treat due in large part to the emergence of drug-resistant forms of TB and the emergence of the HIV epidemic. TB is responsible for the majority of AIDS deaths in Africa.

New TB vaccines are urgently needed. The currently available vaccine, Bacille Calmette-Gurin, provides some protection against pediatric TB but is unreliable in protecting adult pulmonary TB, the most common form of the disease. As a product development partnership, Aeras collaborates and facilitates research in conjunction with numerous scientists in academic, pharmaceutical, biotechnology and government research centers around the world to develop safer and more immunogenic TB vaccines. Globally, nine TB vaccine candidates are currently undergoing clinical testing, and of those, four are directly supported and led by Aeras and its network.

Since the Netherlands's first grant to Aeras and its partners in 2006, four TB vaccine candidates in Aeras' product portfolio have moved into clinical testing in Europe, North America and Africa. Two of those are at the Phase II proof of concept stage and will enroll infants in South Africa, Kenya, Uganda and Mozambique.


'/>"/>

Contact: Annmarie Leadman
aleadman@aeras.org
Aeras Global TB Vaccine Foundation
Source:Eurekalert

Related biology news :

1. Aeras-led research consortium receives FDA support
2. Mississauga teacher awarded prize for excellence in teaching genomics
3. $1,820,000 from NSF awarded to Rutgers-Newark to acquire fMRI dedicated to research
4. SAIC Awarded $23 Million Task Order by Defense Biometrics Identity Management Agency
5. LSUHSC awarded $12 million for cancer, infectious diseases research & research pipeline
6. OU researchers awarded $3M DOE grant to determine effects of climate change on two ecosystems
7. Rutgers part of team awarded $3.3 million National Institutes of Health grant for prostate cancer research
8. Salk Institute Medals to be awarded to Robert Roeder and Irwin Jacobs
9. 2010 Albert Maucher Prize awarded to Potsdam palaeoclimatologist
10. Researcher awarded $2.27 million to study environmental effects on gene copy number
11. Professor Dr. Alexander (Sandy) Lawson is awarded the 2011 Herman Skolnik Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... patient care by providing unparalleled technology to leaders of the medical imaging industry.  As ... added to the range of products distributed by Ampronix. Photo - ... ... ... ...
(Date:5/16/2016)... 16, 2016   EyeLock LLC , a market ... opening of an IoT Center of Excellence in ... the development of embedded iris biometric applications. ... convenience and security with unmatched biometric accuracy, making it ... from DNA. EyeLock,s platform uses video technology to deliver ...
(Date:5/9/2016)... May 9, 2016 Elevay is ... to expanding freedom for high net worth professionals seeking ... today,s globally connected world, there is still no substitute ... ever duplicate sealing your deal with a firm handshake. ... by taking advantage of citizenship via investment programs like ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers use ... 6000i models are higher end machines that use the more unconventional z-dimension of 20mm. ... from the bottom of the cuvette holder. , FireflySci has developed several Agilent ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... NEW YORK , June, 23, 2016  The ... students to envision new ways to harness living systems ... of Modern Art (MoMA) in New York ... more than 130 participating students, showcased projects at MoMA,s ... included Paola Antonelli , MoMA,s senior curator of ...
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
Breaking Biology Technology: